ESCAPE is developing first- and best-in-class novel therapies that are precisely targeted towards a biological pathway or genetically validated target that is perturbed in genetically defined neurodegenerative diseases. Precisely targeting the root cause of disease, combined with deploying our compounds in homogenous genetically defined patient populations, is expected to improve patient outcomes in these otherwise intractable diseases. Taking a selective approach also overcomes liabilities of non-selective approaches.
